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ADAMTS (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif) zinc metalloproteinases are 
active during the synthesis and breakdown of cartilage 
extracellular matrix. Several ADAMTS metalloproteinases 
are capable of degrading aggrecan (e.g., ADAMTS-1, -4, 
-5, -8, -9, -15, -16, and -18), whereas others function as 
procollagen N-propeptidases (e.g., ADAMTS-2, -3, and 
-14).1,2 ADAMTS-12 is expressed in synovium, skeletal 
muscle, cartilage, and fat.3 ADAMTS-12 and ADAMTS-7 
degrade cartilage oligomeric matrix protein (COMP), a 
major noncollagenous protein component of the cartilage 
extracellular matrix.4 COMP is the only known substrate 
ADAMTS-12.3 The exact role of ADAMTS-12 in chondro-
cyte differentiation remains to be elucidated. ADAMTS-12 
is up-regulated during in vitro chondrogenesis as well 
as mouse embryonic limb development with prominent 
expression in physeal chondrocytes.5,6 Ectopic expression 
of ADAMTS-12 in mesenchymal stem cells paradoxically 
inhibited of chondrogenic differentiation.5 ADAMTS-12 
is also implicated in the pathogenesis of osteoarthritis. 
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Abstract
Objective: ADAMTS (a disintegrin and metalloproteinase with thrombospondin type-1 motif) zinc metalloproteinases are 
important during the synthesis and breakdown of cartilage extracellular matrix. ADAMTS-12 is up-regulated during in vitro 
chondrogenesis and embryonic limb development; however, the regulation of ADAMTS-12 expression in cartilage remains 
unknown. The transcription factor c-Maf is a member of Maf family of basic ZIP (bZIP) transcription factors. Expression 
of c-Maf is highest in hypertrophic chondrocytes during embryonic development and postnatal growth. We hypothesize 
that c-Maf and ADAMTS-12 are co-expressed during chondrocyte differentiation and that c-Maf regulates ADAMTS-12 
expression during chondrogenesis. Design: Promoter analysis and species alignments identified potential c-Maf binding 
sites in the ADAMTS-12 promoter. c-Maf and ADAMTS-12 co-expression was monitored during chondrogenesis of stem 
cell pellet cultures. Luciferase expression driven by ADAMTS-12 promoter segments was measured in the presence and 
absence of c-Maf, and synthetic oligonucleotides were used to confirm specific binding of c-Maf to ADAMTS-12 promoter 
sequences. Results: In vitro chondrogenesis from human mesenchymal stem cells revealed co-expression of ADAMTS-12 
and c-Maf during differentiation. Truncation and point mutations of the ADAMTS-12 promoter evaluated in reporter 
assays localized the response to the proximal 315 bp of the ADAMTS-12 promoter, which contained a predicted c-Maf 
recognition element (MARE) at position -61. Electorphoretic mobility shift assay confirmed that c-Maf directly interacted 
with the MARE at position -61. Conclusions: These data suggest that c-Maf is involved in chondrocyte differentiation and 
hypertrophy, at least in part, through the regulation of ADAMTS-12 expression at a newly identified MARE in its proximal 
promoter.
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ADAMTS-12 expression is higher in the cartilage and 
synovium of patients with osteoarthritis compared with 
healthy controls.3,7 Given its roles in both chondrogenesis 
and cartilage degradation, it is important to understand the 
regulation of ADAMTS-12. Currently, the factors that con-
trol ADAMTS-12 expression remain unknown.
The transcription factor c-Maf is a member of Maf fam-
ily of basic ZIP (bZIP) transcription factors.8 Maf proteins 
interact with other proteins through the leucine zipper 
domain. Maf proteins bind to a specific DNA sequences 
termed the “Maf recognition element” (MARE) through the 
basic DNA recognition domain.9 The downstream targets of 
the transcription factor c-Maf in chondrocytes include con-
nective tissue growth factor (CTGF), type II collagen 
(Col2a1), and type 27 collagen (Col27a1).10 The transcrip-
tion factor c-Maf plays a role in chondrogenic differentia-
tion and long bone growth.10,11 Expression of c-Maf is 
highest in hypertrophic chondrocytes during embryonic 
development and postnatal growth.11,12 Mice with a homo-
zygous deletion of c-Maf have abnormal terminal differen-
tiation of hypertrophic chondrocytes accompanied with 
a delay in vascular invasion and reduced ossification.11 
Osteoarthritic chondrocytes overexpress c-Maf.13
The similar expression patterns of both ADAMTS-12 
and c-Maf in osteoarthritis and development led to our 
underlying hypothesis that c-Maf may regulate ADAMTS-12 
expression. Specifically, we hypothesized that c-Maf and 
ADAMTS-12 are co-expressed during hypertrophic chon-
drocyte differentiation and that c-Maf regulates ADAMTS-12 
expression during in vitro chondrogenesis of human mesen-
chymal stem cells via a MARE responsible for c-Maf depen-
dent ADAMTS-12 promoter activation.
Materials and Methods
Sequence Analysis of the  
ADAMTS-12 Proximal Promoter Region
The 3 kbp proximal promoter region of ADAMTS-12 was 
analyzed for putative transcription factor binding sites by the 
TRANSFAC MatInspector (http://www.genomatix.de/cgi-
bin/matinspector/matinspector.pl) and TFSEARCH 
(http://www.cbrc.jp/research/db/TFSEARCH.html) pro-
grams. The transcription start site of ADAMTS-12 was 
predicted by the McPromoter (http://tools.igsp.duke .edu/
generegulation/McPromoterMMII) program.
Gene Expression Analysis during 
Chondrogenic Differentiation of Human 
Bone Marrow Stem Cells (hBMSCs) in 
Three-Dimensional Cell Pellet Culture
Stem cells were isolated from femoral bone marrow aspi-
rates collected from two patients undergoing total knee 
arthroplasty under an institutional review board–approved 
protocol with patient consent according to the method 
described by Pittenger et al.14 and culture-expanded in MS 
medium CGM (Lonza, Basel, Switzerland). To form the 
cell pellets, 5 × 105 passage-2 hBMSCs were centrifuged at 
150 rcf for 5 minutes in conical polypropylene centrifuge 
tubes and maintained in chondrogenic media. Chondrogenic 
media contained DMEM/F-12 supplemented with 50 µg/
mL ascorbate phosphate, 100 µg/mL pyruvate, 1% ITS+ 
Premix (BD Biosciences, Franklin Lakes, NJ), 1% penicillin/
streptomycin, 10 ng/mL recombinant human transforming 
growth factor-β1 (TGF-β1; PeproTech, Rocky Hill, NJ), 
and 500 ng/mL recombinant human insulin-like growth 
factor-1 (IGF-1; R&D Systems, Minneapolis, MN). The 
cell pellets were cultured for up to 11 days with chondro-
genic media changes every 3 to 4 days, with three to four 
pellets from each donor analyzed per time point. RNA was 
isolated from cell pellets using RNeasy total RNA kit 
(Qiagen, Hilden, Germany), quantified on a NanoDrop2000 
spectrophotometer (A260 method), and cDNA was synthe-
sized using High-capacity Reverse Transcriptase reagent 
(Applied Biosystems, Foster City, CA). Real-time quantita-
tive reverse transcription polymerase chain reaction (qRT-
PCR) was performed on an ABI-7700 Sequence Detector 
with Assays-on-Demand TaqMan primers and probes, 
using universal TaqMan conditions (Applied Biosystems). 
The primer/probesets were the following: cMaf-Hs02576418 
_s1, Col2a1-Hs01060345_m1, Col10a1-Hs00166657_m1, 
GAPDH-4326317E, and ADAMTS12-Hs00229594_m1. 
The TaqMan probe for c-Maf is to a region common to both 
isoforms of c-Maf (Lc-Maf and cMaf) and cannot distin-
guish between the two. Gene expression was normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mRNA expression and the fold-change was calculated 
using the 2−ΔΔCt method.
Cloning of ADAMTS-12  
Promoter and c-Maf Constructs
The 3 kbp 5′ upstream region (−2845 to +163) of the human 
ADAMTS-12 gene was cloned using two sets of nested 
PCR primers (Table 1) from a human BAC clone template 
RP11-669P5 (CHORI, Oakland, CA). A series of sequen-
tial truncations of the ADAMTS-12 promoter were sub-
cloned into the pGL4.10 luciferase vector (Promega, 
Madison, WI) via PCR. Specific deletions of 13 nucleotide 
putative MARE sequences at -2311 (Δdistal) and -61 
(Δproximal) were generated in the 3 kbp ADAMTS-12 
promoter or 315 bp promoter constructs using QuickChange 
site-directed mutagenesis (Stratagene, La Jolla, CA). 
Primer sequences used for deletion mutagenesis are shown 
in Table 1.
The coding region of human c-Maf was obtained from 
the cDNA clone (GenBank Accession: BC081542, Open 
Biosystems/ThermoFisher, Lafayette, CO) by PCR using 
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gene-specific primers (Table 1). The full-length, transacti-
vation domain (amino acids 1-125) and binding domain 
(amino acids 252-373) were subcloned into the pFlagCMV2 
mammalian expression vector (Sigma-Aldrich, St Louis, 
MO). Expression was verified by SDS-PAGE on Novex 
precast 4% to 12% gels, followed by blotting onto nitrocel-
lulose and probing with anti-Flag (Sigma #F1804, 1:5,000) 
or anti-GAPDH (Ambion #AM4300, 1:15,000). Detection 
was with horseradish peroxidase–conjugated secondary and 
luminol substrate exposed to standard x-ray film.
ADAMTS-12 Promoter Activation Assays
SW1353 chondrosarcoma cells (ATCC) were seeded to 
1 × 105 cells per well in 12-well plates 24 hours prior to 
transfection. Triplicate wells of cells were cotransfected 
with ADAMTS-12 promoter constructs and Renilla lucifer-
ase pRL-TK (Promega) (molar ratio = 50:1) with or without 
c-Maf constructs. The total amount of transfected DNA 
was kept constant by addition of pUC19 DNA. Luciferase 
activity was measured 48 hours posttransfection with a 
GloMax 20/20 luminometer using a Dual-Luciferase 
Reporter Assay System (Promega). Transfection efficiency 
was normalized with Renilla luciferase activity. Each data 
set is from three different experiments, and statistical com-
parisons were performed using JMP software (SAS, 
Cary, NC) using two-sided t tests with significance set at 
P < 0.05.
Binding of c-Maf to MARE by 
Electrophoretic Mobility Shift Assay (EMSA)
Single-stranded oligonucleotides corresponding to 
ADAMTS-12 MARE, scrambled, and consensus MARE 
sequences (Fig. 5A) were synthesized (Integrated DNA 
Technologies, Coralville, IA) and labeled using Biotin 3′ 
End Labeling Kit (ThermoFisher). Two complimentary 
biotin-labeled oligonucleotides were annealed to generate 
double-stranded probes. SW1353 cells were transiently 
transfected with c-Maf expression plasmid, and nuclear 
extracts were prepared from using NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (ThermoFisher). EMSA 
was performed using the LightShift Chemiluminescent 
EMSA kit, following the manufacturer’s protocol 
(ThermoFisher). Briefly, DNA/protein binding reactions 
were performed using 200 fmol of biotin-labeled probe and 
3 µg of nuclear protein extracts in 1× binding buffer con-
taining 50 ng/µL poly dI:dC and 0.05% NP40 at room 
temperature for 20 minutes. In competition reactions, 
nuclear extracts were incubated with 100-fold molar excess 
of unlabeled oligonucleotides before the addition of probe. 
In supershift assays, nuclear extracts were incubated with 
2 µg of anti-c-Maf antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA) for 15 minutes at room temperature before 
the addition of probe. Samples were resolved in a 6% DNA 
retardation gel (Invitrogen Life Technologies, Carlsbad, 
CA) in 0.5× TBE buffer in a cold room, electro-blotted onto 
Biodyne B nylon membrane (ThermoFisher), and ultravio-
let cross-linked at 120 mJ/cm2 for 1 min. Chemiluminescent 
detection was performed following the manufacturer’s 
protocol.
Statistical Analysis
Experiments were done in triplicate and repeated unless 
otherwise stated. Statistical comparisons were made in 
Microsoft Excel software using Student’s t test with P < 
0.05 considered statistically significant. In all figures, error 
bars indicate standard deviation and significant compari-
sons are indicated with an asterisk (*).
Table 1. Synthetic Oligonucleotide Sequences Used for PCR and EMSA
Clone Forward Primer (5′ → 3′) Reverse Primer (5′ → 3′)
ADAMTS-12 promoter 
genomic PCR
1′ PCR GAGCCAAGCATATAGTCAGCATGTAATAAATG GCTCCTCTGGGCACATGGCATGATTCAGATGTT
















c-Maf Full length gaattcAGCATCAGAACTGGCAATG ggtaccTCACATGAAAAACTCGGG
AD gaattcAGCATCAGAACTGGCAATG ggtaccTCACTGGAGCTGGTGGCTGTT
BD gaattcCGACGAGCGACTGGTGACCATG ggtaccTCACATGAAAAACTCGGG
PCR = polymerase chain reaction; EMSA = electrophoretic mobility shift assay.
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Results
The Proximal Promoter Region of 
ADAMTS-12 Contains Seven Putative  
Maf Binding Sites
Sequence analysis of the 3 kbp promoter indicated that 
ADAMTS-12 promoter does not contain a typical TATA or 
CAAT box. Instead, the proximal promoter has a GC-rich 
region containing four putative Sp1 binding sites (at -89, 
-134, -173, and -227) that are often found in TATA-less 
promoters. Among many predicted transcription factor 
binding sites in the 3 kbp region, the ones with the highest 
core similarity to the consensus sequence are Maf, AP1 
related factor, nuclear factor κB (NFκB), glucocorticoid 
receptor, and hypoxia inducible factor (HIF). Seven Maf 
binding sites were predicted in the proximal 3 kbp 
ADAMTS-12 promoter (Fig. 1A), with varying degrees of 
similarity to the MARE consensus sequences (Fig. 1B).8,9 
The predicted Maf binding sites at -61 and -654 positions 
contain the highest degree of conservation with the MARE 
consensus sequences in their 5′ half of their palindromic 
sequences (Fig. 1B). A sequence comparison of the human 
and mouse ADAMTS-12 promoters revealed that the 
MARE containing region at -61 position is highly con-
served, whereas the sequences at -654 position is not, indi-
cating that the predicted Maf binding site at -61 position 
may be functionally conserved (Fig. 1C).
c-Maf and ADAMTS-12 Are Co-expressed 
During In Vitro Chondrogenic Differentiation
To test whether there is co-expression of c-Maf and 
ADAMTS-12 during chondrogenic differentiation, hBM-
SCs were cultured in three-dimensional cell pellets for 11 
days in chondrogenic media. ADAMTS-12 and c-Maf 
mRNA was monitored by real time qRT-PCR (Fig. 2). 
Differentiation along the chondrogenic pathway was 
Figure 1. Sequence analysis of the proximal 3-kb promoter region of ADAMTS-12. (A) Prominent promoter elements of ADAMTS-12 
promoter are schematically represented. Numbers refer to the upstream position relative to the transcription start site (+1). Not drawn 
to scale. (B) The sequences of each putative Maf binding site in ADAMTS-12 are aligned with MARE consensus sequences. Sequences that 
are identical to those in T-MARE are underlined. (C) Corresponding regions in human and mouse ADAMTS-12 promoter are compared 
for their conservation. Identical sequences are highlighted in black background. The sites that do not have mouse counterparts are left 
blank.
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assessed by the up-regulation of a chondrocyte marker, 
type 2 collagen (Col2a1), and a chondrocyte hypertrophy 
marker, type X collagen (Col10a1). Both markers increased 
during this period, indicating evidence of in vitro chondro-
genesis. The mRNA expression of c-Maf and ADAMTS-12 
increased 12-fold and 11-fold, respectively, during this in 
vitro chondrogenic differentiation assay.
The -315 Region of the ADAMTS-12 
Promoter Is Sufficient for Activity in 
Chondrocytic Cells
We next addressed the transcriptional functionality of the 
ADAMTS-12 promoter. The ability of the ADAMTS-12 
promoter to drive luciferase activity was tested in transient 
transfection assays in SW1353, 293T human embryonic 
kidney cells, and C20/A4 immortalized chondrocytes. The 
3 kbp promoter directed an increase of luciferase activity in 
all cell lines tested compared to the basal control vector 
(Fig. 3B). All subsequent reporter assays were performed 
in SW1353 cells. Sequential 5′ deletions in the promoter 
were generated, which spanned different numbers of the 
predicted Maf binding sites (Fig. 3A). Analysis of all five 
different constructs for basal expression showed that the 
most proximal 315 bp region conferred similar full basal 
expression ability as 3 kbp promoter. No significant 
increase of promoter activity was observed in larger con-
structs. This indicates that the proximal 315 bases are suf-
ficient for the transcriptional basal activity of the human 
ADAMTS-12 promoter (Fig. 3C).
The Proximal -315 Promoter Region of 
ADAMTS-12 Contains an Active MARE Site
To determine the relative contributions of the promoter 
region containing predicted Maf binding sites to c-Maf 
activation, cotransfection experiments were performed with 
each sequential 5′ deletion constructs along with c-Maf 
expression construct. The activity of the 315 bp promoter 
was up-regulated approximately threefold by c-Maf. 
Additional upstream promoter sequences conferred no 
additional activation by c-Maf. This demonstrates that the 
proximal 315 bp region of the ADAMTS-12 promoter was 
sufficient to direct c-Maf-specific transactivation (Fig. 3D).
To test which predicted c-Maf binding sites are neces-
sary for transactivation by c-Maf, we quantified the activi-
ties of the promoters with specific deletions of the putative 
binding sites. The Δproximal deletion abrogated c-Maf-induced 
transactivation, whereas Δdistal did not affect c-Maf-induced 
transactivation (Fig. 4A). Furthermore, the Δproximal 
(-315) also abrogated c-Maf-induced transactivation of 
ADAMTS-12 (-315) (Fig. 4B, compare bars 2 and 8 labeled 
cMaf). Thus, we conclude that the putative MARE at the 
-61 position is active in ADAMTS-12 promoter.
Specificity of c-Maf in Transactivation  
of the ADAMTS-12 Promoter
A functional c-Maf consists of an N-terminal transactiva-
tion domain and C-terminal bZIP binding domain. To fur-
ther establish the specificity of the interaction between 
c-Maf and the ADAMTS-12 promoter, we made two con-
structs of c-Maf, one containing only the binding domain 
(BD) that can act as a dominant-negative mutant and one 
construct containing only the activation domain (AD). 
Neither BD nor AD alone effected ADAMTS-12 promoter 
activity (Fig. 4B, bars 5 and 6), suggesting that both 
domains are required for ADAMTS-12 promoter activa-
tion. BD abrogated full-length (FL) c-Maf-induced transac-
tivation to the empty vector control level, probably because 
of its dominant negative effect (Fig. 4B, bars 1, 2, and 4). 
Figure 2. Co-expression of c-Maf and ADAMTS-12 during in vitro 
chondrogenic differentiation. Endogenous c-Maf and ADAMTS-12 
mRNAs were monitored by qRT-PCR during chondrogenic 
differentiation of hBMSCs in three-dimensional pellet cultures. 
Col2a1 expression was measured to confirm chondrogenic 
differentiation, and Col10a1 expression was measured to confirm 
initiation of chondrocyte hypertrophy. (*) Indicates statistically 
significant difference in gene expression relative to day 0, with 
P < 0.05. qRT-PCR = quantitative reverse transcription polymerase 
chain reaction.
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AD also repressed FL c-Maf-induced transactivation, pos-
sibly by competing for binding to other factors (Fig. 4B, 
bar 3). The decrease of the transactivation by c-Maf trunca-
tions is not due to the change of FL c-Maf protein level, 
because the values of the normalized c-Maf level do not 
reflect the change in the reporter assay (Fig. 4C). Neither 
Figure 3. The activity of ADAMTS-12 promoter is up-regulated by c-Maf. (A) Schematic diagram of the sequential 5′ deletions of 
ADAMTS-12 promoter region that were used to map c-Maf-response element. Ovals represent predicted putative Maf binding sites. 
Not drawn to scale. (B) Basal transcriptional activity of this 3-kb promoter was measured in three different cell lines using luciferase 
assays. Bars indicate fold change from pGL4.10 control vector. (C) The basal activities of each truncated ADAMTS-12 promoter were 
measured in the SW1353 chondrosarcoma cell line. (D) To measure the activation of the ADAMTS-12 promoter by c-Maf above basal 
levels, c-Maf or empty expression vector (v) were cotransfected with the various ADAMTS-12 promoter truncation constructs. Assays 
were run in triplicate and the average from three independent experiments is shown with standard deviation. (*) Indicates statistically 
significant difference in luciferase activity relative to the respective controls, with p < 0.05.
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Figure 4. Functional c-Maf-response element was identified in the ADAMTS-12 promoter. (A) Precise deletions of 13-nt predicted 
MARE sequences at the -61 (∆proximal) or -2311 (∆distal) regions were deleted in the context of the otherwise intact 3-kb ADAMTS-12 
promoter. The effect of these deletions on c-Maf-induced transactivation was tested by luciferase assay. c-Maf (M), empty expression 
vector (v). ∆proximal, but no (B) 13-nt of predicted MARE sequences at -61 [∆proximal(-315)] region were deleted in the context of 
a truncated (-315 bp) promoter construct. The effect of the AD and BD c-Maf domains on the transactivation function of FL c-Maf was 
tested by cotransfection, and results show that neither domains activated the ADAMTS-12 promoter on their own, whereas they both 
inhibited the activity of full-length c-Maf. (C) Expression of FL, AD, and BD was detected by western blot analysis. Densitometric analysis 
was performed using Adobe Photoshop by measuring band intensities of GAPDH and c-Maf. Normalized FL c-Maf levels are shown as 
percentage of c-Maf alone. (D) The effect of Sox9, alone or with c-Maf, on ADAMTS-12 promoter activity was tested, and Sox9 did not 
activate the ADAMTS-12 promoter alone or in synergy with c-Maf. FL = full length c-Maf; AD = activating domain of c-Maf; BD = DNA 
binding domain of c-Maf. Assays and analyses were performed in triplicate, and the average of three independent experiments is shown, 
* Indicates p < 0.05.
BD nor AD effected Δproximal (-315) promoter activity 
(Fig. 4B, lanes 9-12). In addition, we tested for an interac-
tion with the Sox9 transcription factor and found that Sox9 
itself did not confer any transactivation on ADAMTS-12 
promoter, either alone or in combination with c-Maf (Fig. 4D).
c-MAF Directly Binds to the Proximal MARE 
Sequences of ADAMTS-12 In Vitro
To examine whether c-Maf directly binds to the proximal 
MARE sequences in ADAMTS-12 promoter in vitro, we 
performed EMSA using the proximal MARE sequences as 
a probe and the nuclear extract from c-Maf-transfected 
SW1353 cells. The 23 bp MARE probe (position from -66 
through -44) contains 13 nucleotides of predicted MARE 
sequences and 5 extra nucleotides at each end (Fig. 5A). As 
a negative control, the sequences were scrambled so that no 
statistically significant putative transcription factor binding 
sites were detected in these scrambled sequences using 
TFSEARCH program (data not shown). The consensus 
MARE sequences (T-MARE) were used as a positive 
control. EMSA with proximal MARE probe revealed two 
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shifted bands (bands 1 and 2). Excess of nonlabeled probe 
disturbed the specific shifted band (band 1), but not the 
nonspecific band (band 2) (Fig. 5, lanes 1-3). Scrambled 
negative control probe did not generate specific shifted 
band (Fig. 5, lanes 5 and 6). We observed disappearance of 
band 1 when anti-c-Maf antibody was added to the binding 
reaction (Fig. 5, lane 4), which may occur through disrup-
tion of the protein–DNA binding. These results confirm 
that a specific binding interaction occurs between c-Maf 
and the MARE sequence at -61 of the human ADAMTS-12 
promoter.
Discussion
We found that ADAMTS-12 expression was up-regulated 
during chondrogenesis in vitro, which is consistent with 
existing literature.5 As the regulation of ADAMTS-12 
expression remains largely unknown, we further examined 
the human and mouse ADAMTS-12 promoters for poten-
tial transcription factor binding sites and identified several 
MARE sites for c-Maf binding. Induction of ADAMTS-12 
expression during chondrogenesis in vitro coincided with 
c-Maf induction, suggesting a functional relationship 
between the two during chondrogenesis. This interaction is 
substantiated by reports that hypertrophic chondrocytes 
express c-Maf during mouse embryonic development and 
that c-Maf facilitates terminal chondrocyte differentiation 
in postnatal mice.11,12 Of the potential MARE sites we iden-
tified in the human ADAMTS-12 promoter, we found that 
a single MARE site at position -61 was sufficient to confer 
regulation of ADAMTS-12 expression by c-Maf in our 
experimental systems.
In addition to cMaf, the expression of ADAMTS-12 
mRNA was also shown to be regulated by parathyroid hor-
mone related peptide (PTHrP).5 In this context, it is possible 
that ADAMTS-12 may also inhibit hypertrophic chondro-
cyte differentiation in some circumstances.5 PTHrP main-
tains proliferation and inhibits chondrocyte hypertrophy 
in the physis.15 ADAMTS-12-null mice have no apparent 
growth defect but their cartilage has not been specifically 
examined.16 Additionally, c-Maf-null mice display advanced 
terminal chondrocyte differentiation.11 Hence, future stud-
ies will focus on the in vivo localization of ADAMTS-12 
and c-Maf in physeal cartilage as well as ADAMTS-12 
expression in c-Maf-null mice, to elucidate the func-
tional interaction of these proteins in chondrogenesis and 
hypertrophy.
In addition to ADAMTS-12, at least two c-Maf 
target genes are also involved in chondrocyte differentia-
tion, namely, CTGF and matrix metalloproteinase-13 
(MMP-13).17,18 CTGF and MMP-13 are localized in hyper-
trophic chondrocytes during mouse skeletal development.17 
The expression patterns of CTGF and MMP-13 overlap 
with that of c-Maf.11,17 The CTGF promoter does not con-
tain a consensus MARE-like sequence, whereas the MMP-
13 promoter contains sequences highly homologous to 
T-MARE. Col 2a1 and Col27a1 were also identified as tar-
gets of longer transcriptional variant of c-Maf (Lc-Maf).19,20 
The Lc-Maf-responsive sequences in Col2a1 and Col27a1 
promoters do not share any homology with MARE consen-
sus sequence. Studies have been unable to demonstrate colo-
calization of Lc-Maf with Col2a1 during precartilaginous 
mesenchymal condensations or Col27a1 in the proliferating 
and prehypertrophic chondrocytes.19,20 Finally, Col10a1 is a 
marker of chondrocyte hypertrophy, but it remains to be 
determined if c-Maf also regulates Col10a1 expression.
Members of the Maf transcription factor family form 
heterodimers with other Maf and bZIP transcription factors 
through their leucine zipper domains.10 Maf proteins may 
also interact with non-bZIP proteins.10 Sox9, an important 
regulator of chondrogenesis, has been shown to synergize 
with Lc-Maf to activate Col2a1 and Col27a1 expres-
sion.19,20 However, in our system we did not observe a syn-
ergistic interaction between Sox9 and c-Maf during the 
activation of the 3 kbp ADAMTS-12 promoter (Fig. 4D). 
Aberrant expression of c-Maf nonchondrocytic cells has a 
wide range of effects from proliferation to apoptosis, 
depending on the cellular context.21-23 We did not observe 
any change in cell number related to apoptosis or proliferation 
on c-Maf overexpression in SW1353 and C20/A4 cells 
(data not shown).
Figure 5. c-Maf binds to the proximal MARE in ADAMTS-12 
promoter in vitro. (A) Sequences are shown for 23-bp promoter 
region (bp -66 through -44) containing functionally defined 
proximal (-61) MARE in ADAMTS-12, and the scrambled negative 
control. (B) End-labeled probes were incubated with nuclear 
extract of c-Maf-transfected SW1353 cells. F, free probe, 1, specific 
DNA-protein complex formed by c-Maf, 2, nonspecific band which 
does not disappear with excess of nonlabeled specific competitor. 
Addition of anti-c-Maf antibody disrupted the band 1.
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There are two types of MARE sites, T-MARE and 
C-MARE, which are perfect palindromic 13 and 14 nucle-
otides sequences, respectively.9 However, the Maf tran-
scription factors frequently activate many genes through 
response elements that contain only one half of the palin-
dromic MARE.10 The MARE consensus sequences gener-
ated by analyzing known naturally occurring Maf binding 
sites revealed that the 5′ half region is more conserved than 
the 3′ half.8 Consistent with this observation, we found that 
the functional c-Maf binding site identified in the 
ADAMTS-12 promoter has a well-conserved 5′ half region 
but a less conserved 3′ half region. However, despite being 
not so well conserved with other MARE sequences 
throughout the genome, the sequence of the proximal 
region of the ADAMTS-12 promoter is highly conserved 
between human and mouse, indicating that this region is 
important for the regulation of ADAMTS-12 expression 
across species.
Our population is aging and the prevalence of osteoar-
thritis is increasing. As of today, there is no cure for osteo-
arthritis, and thus a greater understanding of the factors that 
influence cartilage homeostasis and arthritis progression is 
required. In this article, we show that the cartilage-degrad-
ing enzyme ADAMTS-12 is regulated by the transcription 
factor c-MAF. We demonstrated that ADAMTS-12 is 
co-expressed with c-Maf during in vitro chondrogenic dif-
ferentiation. The ADAMTS-12 promoter was up-regulated 
by c-Maf and this up-regulation occurred via a direct inter-
action with the proximal c-Maf binding site at position -61 
of the ADAMTS-12 promoter. A primary target of 
ADAMTS-12 proteolytic activity is cartilage oligomeric 
matrix protein (COMP), and the concentration of COMP 
fragments in serum is used as a biomarker for arthritis.3 We 
have recently shown enhanced activity of TGFβ1 when 
bound to COMP,24 and this raises the intriguing possibility 
that proteolytic activity by ADAMTS-12 may indirectly 
affect TGFβ activity in osteoarthritic cartilage. Further 
studies will be required to elucidate a definitive role of 
c-Maf in regulating ADAMTS-12-mediated matrix degra-
dation during the progression of osteoarthritis and embry-
onic development.
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